Rare disease group challenges effectiveness of state drug price caps

Nine states have launched Prescription Drug Affordability Boards to curb rising costs, with Colorado and Maryland already implementing payment caps on medications like Enbrel and Jardiance. However, the report authored by Jennifer Snow of Apteka Policy suggests these measures are fundamentally misaligned with pharmaceutical supply chain mechanics. By capping what payers reimburse providers, states create a ceiling that rarely translates into lower pharmacy counter prices for consumers.

The analysis warns that these policies threaten to destabilize access to specialized treatments. When reimbursement levels fall below operational costs, pharmacies and providers may be forced to stop stocking specific drugs to avoid financial losses. This risk is most acute for rare disease patients who lack therapeutic alternatives. Furthermore, the report notes that state-level caps can inadvertently reset Medicaid rebate floors nationwide, creating federal policy conflicts. Instead of current price-capping strategies, the organization advocates for direct interventions like capped copay programs and reinsurance, which target patient costs without compromising the distribution networks patients rely on.